Clinical utilities of aromatase inhibitors in breast cancer

References

• ThompsonEAJrSiiteriPKUtilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedioneJ Biol Chem197424917536453724153532
   PubMed Web of Science ®Google Scholar
• ChenSABesmanMJSparkesRSHuman aromatase: cDNA cloning, Southern blot analysis, and assignment of the gene to chromosome 15DNA19887127383390233
   PubMedGoogle Scholar
• FisherBCostantinoJPRedmondCKFisherERWickerhamDLCroninWMEndometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical adjuvant Breast and Bowel Project (NSABP) B-14J Natl Cancer Inst19948675275378133536
   PubMed Web of Science ®Google Scholar
• JordanVCTamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancerAnnu Rev Pharmacol Toxicol1995351952117598491
   PubMed Web of Science ®Google Scholar
• SchwarzelWCKruggelWGBrodieHJStudies on the mechanism of estrogen biosynthesis. 8. The development of inhibitors of the enzyme system in human placentaEndocrinology19739238668804267111
   PubMed Web of Science ®Google Scholar
• ChumsriSHowesTBaoTSabnisGBrodieAAromatase, aromatase inhibitors, and breast cancerJ Steroid Biochem Mol Biol20111251–2132221335088
   PubMed Web of Science ®Google Scholar
• SantenRJBrodieHSimpsonERSiiteriPKBrodieAHistory of aromatase: saga of an important biological mediator and therapeutic targetEndocr Rev200930434337519389994
   PubMed Web of Science ®Google Scholar
• BulunSELinZImirGRegulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatmentPharmacol Rev200557335938316109840
   PubMed Web of Science ®Google Scholar
• van LandeghemAAPoortmanJNabuursMThijssenJHEndogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissueCancer Res1985456290029063986816
   PubMed Web of Science ®Google Scholar
• ChetriteGSCortes-PrietoJPhilippeJCWrightFPasqualiniJRComparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissuesJ Steroid Biochem Mol Biol2000721–2232710731634
   PubMed Web of Science ®Google Scholar
• GeislerJBerntsenHLonningPEA novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissueJ Steroid Biochem Mol Biol200072525926410822015
   PubMed Web of Science ®Google Scholar
• FabianCJThe what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancerInt J Clin Pract200761122051206317892469
   PubMed Web of Science ®Google Scholar
• Rodriguez-WallbergKAOktayKFertility preservation in women with breast cancerClin Obstet Gynecol201053475376221048442
   PubMed Web of Science ®Google Scholar
• SmithIEDowsettMYapYSAdjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelinesJ Clin Oncol200624162444244716735701
   PubMed Web of Science ®Google Scholar
• MouridsenHGershanovichMSunYSuperior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer GroupJ Clin Oncol200119102596260611352951
   PubMed Web of Science ®Google Scholar
• BonneterreJBuzdarANabholtzJMAnastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinomaCancer20019292247225811745278
   PubMed Web of Science ®Google Scholar
• NabholtzJMBuzdarAPollakMAnastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study GroupJ Clin Oncol200018223758376711078488
   PubMed Web of Science ®Google Scholar
• MouridsenHTAromatase inhibitors in advanced breast cancerSemin Oncol2004316 Suppl 123815719595
   PubMed Web of Science ®Google Scholar
• JoelPBTraishAMLanniganDAEstradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinaseJ Biol Chem19982732113317133239582378
   PubMed Web of Science ®Google Scholar
• MacedoLFSabnisGBrodieAPreclinical modeling of endocrine response and resistance: focus on aromatase inhibitorsCancer20081123 Suppl67968818072255
   PubMed Web of Science ®Google Scholar
• MacedoLFSabnisGJGoloubevaOGBrodieACombination of anastrozole with fulvestrant in the intratumoral aromatase xenograft modelCancer Res20086893516352218451180
   PubMed Web of Science ®Google Scholar
• BerghJJonssonPELidbrinkEKFACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancerJ Clin Oncol201230161919192522370325
   PubMed Web of Science ®Google Scholar
• MehtaRSBarlowWEAlbainKSCombination anastrozole and fulvestrant in metastatic breast cancerN Engl J Med2012367543544422853014
   PubMed Web of Science ®Google Scholar
• JohnstonSRKilburnLSEllisPFulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trialLancet Oncol2013141098999823902874
   PubMed Web of Science ®Google Scholar
• BursteinHJPrestrudAASeidenfeldJAmerican Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast CancerJ Clin Oncol201028233784379620625130
   PubMed Web of Science ®Google Scholar
• CuzickJSestakIBaumMEffect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10–year analysis of the ATAC trialLancet Oncol201011121135114121087898
   PubMed Web of Science ®Google Scholar
• BIG 1-98 Collaborative GroupMouridsenHGiobbie-HurderALetrozole therapy alone or in sequence with tamoxifen in women with breast cancerN Engl J Med2009361876677619692688
   PubMed Web of Science ®Google Scholar
• KaufmannMJonatWHilfrichJEidtmannHGademannGZunaIvon MinckwitzGImproved overall survival in postmenopausal women with early breast cancer after anastrozole initiated aftertreatment with tamoxifen compared with continued tamoxifen: the ARNO 95 StudyJ Clin Oncol200725192664267017563395
   PubMed Web of Science ®Google Scholar
• BoccardoFRubagottiAGuglielminiPFiniAPaladiniGMesitiMRinaldiniSwitching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trialAnn Oncol200617Suppl 7vii10416760270
   PubMed Web of Science ®Google Scholar
• CoombesRCHallEGibsonLJParidaensRJassemJDelozierTJonesSEIntergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancerN Engl J Med2004350111081109215014181
   PubMed Web of Science ®Google Scholar
• JakeszRGreilRGnantMExtended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6aJ Natl Cancer Inst200799241845185318073378
   PubMed Web of Science ®Google Scholar
• GossPEIngleJNMartinoSRandomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17J Natl Cancer Inst200597171262127116145047
   PubMed Web of Science ®Google Scholar
• MamounasEPJeongJHWickerhamDLBenefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical adjuvant Breast And Bowel Project B-33 trialJ Clin Oncol200826121965197118332472
   PubMed Web of Science ®Google Scholar
• College of American PathologistsBreast Cancer Invasive Lobular CarcinomaCollege of American Pathologists2010 Available from: http://www.cap.org/apps/docs/reference/myBiopsy/BreastInvasiveLobularCarcinoma.pdfAccessed February 15, 2015
   Google Scholar
• GnantMMlineritschBSchippingerWEndocrine therapy plus zoledronic acid in premenopausal breast cancerN Engl J Med2009360767969119213681
   PubMed Web of Science ®Google Scholar
• PaganiOReganMMWalleyBAAdjuvant exemestane with ovarian suppression in premenopausal breast cancerN Engl J Med2014371210711824881463
   PubMed Web of Science ®Google Scholar
• FrancisPAReganMMFlemingGFAdjuvant Ovarian Suppression in Premenopausal Breast CancerN Engl J Med2015372543644625495490
   PubMed Web of Science ®Google Scholar
• HershmanDLPerfecting Breast-Cancer Treatment – Incremental Gains and Musculoskeletal PainsN Engl J Med2015372547747825495491
   PubMed Web of Science ®Google Scholar
• RugoHSHormone therapy in premenopausal women with early-stage breast cancerN Engl J Med2014371217517625006724
   PubMed Web of Science ®Google Scholar
• WatersEACroninKAGraubardBIHanPKFreedmanANPrevalence of tamoxifen use for breast cancer chemoprevention among U.S. womenCancer Epidemiol Biomarkers Prev201019244344620142242
   PubMed Web of Science ®Google Scholar
• WatersEAMcNeelTSStevensWMFreedmanANUse of tamoxifen and raloxifene for breast cancer chemoprevention in 2010Breast Cancer Res Treat2012134287588022622807
   PubMed Web of Science ®Google Scholar
• GossPEIngleJNAles-MartinezJEExemestane for breast-cancer prevention in postmenopausal womenN Engl J Med2011364252381239121639806
   PubMed Web of Science ®Google Scholar
• CuzickJSestakIForbesJFAnastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trialLancet201438399221041104824333009
   PubMed Web of Science ®Google Scholar
• LoprinziCLBartonDLQinRNonestrogenic management of hot flashesJ Clin Oncol201129293842384621911722
   PubMed Web of Science ®Google Scholar
• NiravathPAromatase inhibitor-induced arthralgia: a reviewAnn Oncol20132461443144923471104
   PubMed Web of Science ®Google Scholar
• HenryNLBanerjeeMWichaMPilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptomsCancer2011117245469547521692065
   PubMed Web of Science ®Google Scholar